Newborn Screening Market is expected to reach US$ 2,484.16 million by 2030

Dry Blood Spot Tests Segment to Lead Newborn Screening Market Based on Test Type During 2022–2030

According to our new research study on “Newborn Screening Market Forecast To 2030 – Global Analysis – by Product Type, Technology, Test Type, and End User,” the newborn screening market size was valued at US$ 1,206.74 million in 2022 and is projected to reach US$ 2,484.16 million by 2030; it is estimated to register a CAGR of 9.4% from 2022 to 2030. Key factors driving the newborn screening market growth include the surging funding from government sectors for newborn screening, rising burden of congenital diseases, and increasing prevalence of newborn disorders.

Based on test type, the newborn screening market is segmented into dry blood spot tests, hearing screen tests, critical congenital heart disease tests, and other tests. The dry blood spot tests segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR during 2022-2030. A dry blood sport test is also called a heel stick test. A medical professional collects a few drops of blood from the baby’s heel on filter paper. After the sample dries, it is sent to hospitals, clinics, or diagnostic laboratories. Different punches of varying sizes are taken from the blood spots to be tested for various disease conditions. The baby's blood is collected on the newborn screening card in five circles. Dried blood spots are used to obtain a baby’s biological information (including genetic information) that may be useful for studying its congenital disabilities and diseases. DBS might also be used to evaluate certain infections or the effects of certain substances (such as lead) on a developing baby. The blood spot screening test helps detect babies with sickle cell disease. The babies diagnosed with such conditions can receive early interventions such as vaccinations, medicines, and dietary supplements after detection, which will help them live healthier lives. Other major applications of DBS testing include the detection of hepatitis C virus (HCV), hepatitis B virus (HBV), antibodies to HBV and HCV core antigens, HCV RNA, and human immunodeficiency virus (HIV).

Newborn Screening Market, by Region, 2022(%)

Source: The Insight Partners Analysis

North America accounted for the largest share of the global newborn screening market in 2022. The demand for newborn screening services has increased significantly with the surging awareness among parents and healthcare professionals about the importance of early screening for identifying and managing congenital disorders. Additionally, improvements in medical technology have been crucial in enhancing newborn screening capabilities—automation in laboratories has boosted screening accuracy, speed, and cost-effectiveness. This has made it possible for medical professionals to give thorough newborn screening panels that cover a larger spectrum of genetic and metabolic disorders. Favorable legislation and regulatory measures also benefit the newborn screening market in North America. Many states and provinces have implemented mandatory newborn screening programs, ensuring all infants are screened shortly after birth. For instance, every state in the US offers newborn screening as a public health program; yearly, ~4 million babies are screened under this program for illnesses that aren't often present at the time of delivery. The Texas Department of Health and Human Services began screening newborns for spinal muscular atrophy (SMA) in June 2021. Thus, the newborn screening market in North America is flourishing with increased awareness, technological advancements, supportive policies, and growing congenital disorder prevalence.

Medtronic Plc, LifeCell International Pvt Ltd, Zentech SA, Trivitron Healthcare, PerkinElmer Inc, Waters Corp, Bio-Rad Laboratories Inc, Masimo Corp, Natus Medical Inc, Baebies Inc, and MRC Holland BV are among the leading companies operating in the newborn screening market.  

Based on product type, the newborn screening market is segmented into reagents and assay kits, and instruments. In terms of technology, the newborn screening market is segmented into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assays, pulse oximetry screening technology, and other technologies. Based on test type, the newborn screening market is segmented into dry blood spot tests, hearing screen tests, critical congenital heart disease tests, and other tests. In terms of end user, the newborn screening market is segmented into hospitals and clinics, and diagnostic laboratories. The newborn screening market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of MEA), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com